In a regulatory filing, ShotSpotter disclosed that its CFO Alan Stewart bought 7.5K shares of common stock on March 3rd in a total transaction size of $285K.

In a regulatory filing, TriMas director Herbert K. Parker disclosed the sale of 21,158 common shares of the company on March 2 at a price of $32.16 per share.

In a regulatory filing, PDC Energy director Anthony J. Crisafio disclosed the sale of 17,000 common shares of the company on March 3 at a price of $36.30 per share.

On March 3, Oportun, Inc. a subsidiary of Oportun Financial Corporation, received a Civil Investigative Demand from the Consumer Financial Protection Bureau. The stated purpose of the CID is to determine whether small-dollar lenders or associated persons, in connection with lending and debt-collection practices, have not been in compliance with certain federal consumer protection laws over which the CFPB has jurisdiction, the company disclosed in a regulatory filing. The information requests in the CID focus on Oportun's legal collection practices from 2019 to 2021 and hardship treatments offered during the COVID-19 pandemic. "The Company believes its practices have been in full compliance with CFPB guidance and that it has followed all published authority with respect to its practices, and the Company intends to cooperate with the CFPB. At this time, the Company is unable to predict the outcome of this CFPB investigation, including whether the investigation will result in any action or proceeding against the Company or in any changes to its practices," it said.

Avery Dennison VP Deena Baker disclosed in a filing that she had sold 2,500 shares of company stock at $179.46 per share on March 3, for a total transaction amount of $448,653.

Oxford Immunotec Global announced that it has released the T-SPOT.COVID test, a CE marked ELISPOT based test intended for qualitative detection of a cell mediated immune response to SARS-CoV-2 in human whole blood. The company has filed an EUA request to the FDA for the test. Serology does not give the full picture of the adaptive immune response to SARS-CoV-2 infection. Antibodies are not always produced in response to SARS-CoV-2 infection, or may be delayed1,2. Antibodies can also wane quickly after infection4 and reports show T cells may be more long lived than the antibody response3. In the absence of an antibody response, the T cell response may be protective from SARS-CoV-2 infection5. In a clinical study using samples collected in the US, the T-SPOT.COVID test was proven to detect a SARS-CoV-2 cell mediated immune response in PCR positive individuals, even with negative serology test results6. The T-SPOT.COVID test therefore complements results obtained by antibody serology to give a more comprehensive view of an individual's adaptive immune response to SARS-CoV-2 infection. The test could also be used, for example, alongside serology tests to support clinical assessment of individuals who present with suspected COVID-19 but are PCR negative.